<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300495</url>
  </required_header>
  <id_info>
    <org_study_id>2005P000376</org_study_id>
    <nct_id>NCT00300495</nct_id>
  </id_info>
  <brief_title>Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection</brief_title>
  <official_title>Phase III Study of Preoperative Amiodarone for Prevention of Atrial Fibrillation After Lung Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is a very common complication of pulmonary resection. Patients who
      develop atrial fibrillation require additional treatment and are more likely to stay in the
      hospital for longer period of time increasing the costs associated with the operation. We
      propose a randomized controlled trial to see if oral amiodarone given for one week before
      surgery can prevent atrial fibrillation after pulmonary resection. We plan to evaluate the
      incidence of atrial fibrillation in patients who received preoperative amiodarone and compare
      them to the incidence of atrial fibrillation in patients who did not received preoperative
      amiodarone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is a very common complication of pulmonary resection. Patients who
      develop atrial fibrillation require additional treatment and are more likely to stay in the
      hospital for longer period of time increasing the costs associated with the operation.

      We propose a study to see if oral amiodarone given for one week before surgery can prevent
      atrial fibrillation after pulmonary resection. We plan to evaluate the incidence of atrial
      fibrillation in patients who received preoperative amiodarone and compare them to the
      incidence of atrial fibrillation in patients who did not received preoperative amiodarone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to accrual total number of participants during study period.
  </why_stopped>
  <start_date type="Actual">February 2006</start_date>
  <completion_date type="Actual">October 13, 2009</completion_date>
  <primary_completion_date type="Actual">October 13, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Post-operative Atrial Fibrillation</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with post-operative atrial fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Post-operative Hospital Stay</measure>
    <time_frame>1 week on average</time_frame>
    <description>Length of hospital stay after the operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1 - Amiodarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative amiodarone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm, standard care with no perioperative amiodarone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Perioperative orally administered</description>
    <arm_group_label>1 - Amiodarone</arm_group_label>
    <other_name>Cordarone</other_name>
    <other_name>Pacerone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control arm, standard care</intervention_name>
    <description>Control</description>
    <arm_group_label>2 - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resectable lung nodule or mass

        Exclusion Criteria:

          -  Allergy to amiodarone

          -  Currently taking amiodarone

          -  Documented atrial fibrillation within past 12 months

          -  Known pulmonary fibrosis

          -  Known hepatic dysfunction

          -  Thyroid disease

          -  2nd or 3rd degree heart block

          -  Severe SA node disease

          -  Bradycardia-induced syncope

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm M DeCamp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2006</study_first_submitted>
  <study_first_submitted_qc>March 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <results_first_submitted>March 20, 2017</results_first_submitted>
  <results_first_submitted_qc>March 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2017</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Malcolm DeCamp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Pulmonary resection</keyword>
  <keyword>Post-operative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient in the control group was excluded because, after patient was enrolled, patient had mediastinoscopy that showed more advanced disease. Thus, patient did not undergo lung resection. Therefore this patient was excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 - Amiodarone</title>
          <description>Perioperative amiodarone
Amiodarone: Perioperative orally administered
Patients received 200 mg of amiodarone three times a day for one week prior to surgery and 200 mg twice a day for one week after the surgery</description>
        </group>
        <group group_id="P2">
          <title>2 - Control</title>
          <description>Control arm, standard care with no perioperative amiodarone
Control arm, standard care: Control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 - Amiodarone</title>
          <description>Perioperative amiodarone
Amiodarone: Perioperative orally administered</description>
        </group>
        <group group_id="B2">
          <title>2 - Control</title>
          <description>Control arm, standard care with no perioperative amiodarone
Control arm, standard care: Control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age &gt; 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Post-operative Atrial Fibrillation</title>
        <description>Number of patients with post-operative atrial fibrillation</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Amiodarone</title>
            <description>Perioperative amiodarone
Amiodarone: Perioperative orally administered
Patients received 200 mg of amiodarone three times a day for one week prior to surgery and 200 mg twice a day for one week after the surgery</description>
          </group>
          <group group_id="O2">
            <title>2 - Control</title>
            <description>Control arm, standard care with no perioperative amiodarone
Control arm, standard care: Control</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Post-operative Atrial Fibrillation</title>
          <description>Number of patients with post-operative atrial fibrillation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Post-operative Hospital Stay</title>
        <description>Length of hospital stay after the operation</description>
        <time_frame>1 week on average</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Amiodarone</title>
            <description>Perioperative amiodarone
Amiodarone: Perioperative orally administered
Patients received 200 mg of amiodarone three times a day for one week prior to surgery and 200 mg twice a day for one week after the surgery</description>
          </group>
          <group group_id="O2">
            <title>2 - Control</title>
            <description>Control arm, standard care with no perioperative amiodarone
Control arm, standard care: Control</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Post-operative Hospital Stay</title>
          <description>Length of hospital stay after the operation</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="2"/>
                    <measurement group_id="O2" value="5" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week prior to surgery and 30 days after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 - Amiodarone</title>
          <description>Perioperative amiodarone
Amiodarone: Perioperative orally administered
Patients received 200 mg of amiodarone three times a day for one week prior to surgery and 200 mg twice a day for one week after the surgery</description>
        </group>
        <group group_id="E2">
          <title>2 - Control</title>
          <description>Control arm, standard care with no perioperative amiodarone
Control arm, standard care: Control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Min Kim</name_or_title>
      <organization>Houston Methodist Hospital</organization>
      <phone>7134415177</phone>
      <email>mpkim@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

